Published in Infect Immun on January 01, 1988
Cholera. Clin Microbiol Rev (1995) 12.33
Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med (1988) 9.19
Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev (1992) 5.15
Identification of a vibrio cholerae RTX toxin gene cluster that is tightly linked to the cholera toxin prophage. Proc Natl Acad Sci U S A (1999) 3.75
Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev (1996) 3.46
Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci U S A (1991) 3.43
CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor. Proc Natl Acad Sci U S A (1993) 3.34
Accessory cholera enterotoxin (Ace), the third toxin of a Vibrio cholerae virulence cassette. Proc Natl Acad Sci U S A (1993) 2.81
Self-limiting nature of seasonal cholera epidemics: Role of host-mediated amplification of phage. Proc Natl Acad Sci U S A (2005) 2.80
Transmissibility of cholera: in vivo-formed biofilms and their relationship to infectivity and persistence in the environment. Proc Natl Acad Sci U S A (2006) 2.54
Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans. J Clin Invest (1990) 2.33
Identification of a domain within the multifunctional Vibrio cholerae RTX toxin that covalently cross-links actin. Proc Natl Acad Sci U S A (2004) 2.31
Cloning of a gene (zot) encoding a new toxin produced by Vibrio cholerae. Infect Immun (1992) 2.18
Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J Clin Invest (1995) 2.14
The extracellular cytolysin of Vibrio vulnificus: inactivation and relationship to virulence in mice. Infect Immun (1991) 1.87
Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One (2007) 1.86
Molecular analysis of Vibrio cholerae O1, O139, non-O1, and non-O139 strains: clonal relationships between clinical and environmental isolates. Appl Environ Microbiol (2001) 1.86
Characterization of Vibrio cgolerae non-O1 serogroups obtained from an outbreak of diarrhea in Lima, Peru. J Clin Microbiol (1995) 1.82
Development and testing of a nonradioactive DNA oligonucleotide probe that is specific for Vibrio cholerae cholera toxin. J Clin Microbiol (1992) 1.71
Hemolysin and the multifunctional autoprocessing RTX toxin are virulence factors during intestinal infection of mice with Vibrio cholerae El Tor O1 strains. Infect Immun (2007) 1.68
Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect Immun (1990) 1.64
Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun (1990) 1.55
Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun (1989) 1.41
Immunogenicity of Vibrio cholerae O1 toxin-coregulated pili in experimental and clinical cholera. Infect Immun (1991) 1.39
An in vivo expression technology screen for Vibrio cholerae genes expressed in human volunteers. Proc Natl Acad Sci U S A (2007) 1.38
Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun (1992) 1.35
Vibrio cholerae O1 adherence to villi and lymphoid follicle epithelium: in vitro model using formalin-treated human small intestine and correlation between adherence and cell-associated hemagglutinin levels. Infect Immun (1988) 1.35
CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain. Infect Immun (1993) 1.35
Cytotoxic cell vacuolating activity from Vibrio cholerae hemolysin. Infect Immun (2000) 1.34
Comparison of the Vibrio cholerae hemagglutinin/protease and the Pseudomonas aeruginosa elastase. Infect Immun (1990) 1.31
Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate. Infect Immun (1999) 1.31
Detection of Escherichia coli, Salmonella spp., Shigella spp., Yersinia enterocolitica, Vibrio cholerae, and Campylobacter spp. enteropathogens by 3-reaction multiplex polymerase chain reaction. Diagn Microbiol Infect Dis (2008) 1.30
Cholera enterotoxin production in Vibrio cholerae O1 strains isolated from the environment and from humans in Japan. Appl Environ Microbiol (1991) 1.28
Analysis of expression of toxin-coregulated pili in classical and El Tor Vibrio cholerae O1 in vitro and in vivo. Infect Immun (1992) 1.27
Indirect measurement of intestinal immune responses to an orally administered attenuated bacterial vaccine. Infect Immun (1992) 1.25
Monoclonal immunoglobulin A antibodies directed against cholera toxin prevent the toxin-induced chloride secretory response and block toxin binding to intestinal epithelial cells in vitro. Infect Immun (1993) 1.19
Net fluid secretion and impaired villous function induced by colonization of the small intestine by nontoxigenic colonizing Escherichia coli. Infect Immun (1990) 1.17
Potent membrane-permeabilizing and cytocidal action of Vibrio cholerae cytolysin on human intestinal cells. Infect Immun (1997) 1.15
Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect Immun (2010) 1.12
Comparison of Vibrio cholerae pathogenicity islands in sixth and seventh pandemic strains. Infect Immun (2001) 1.09
Vibrio cholerae evades neutrophil extracellular traps by the activity of two extracellular nucleases. PLoS Pathog (2013) 1.07
Vibrio cholerae flagellins induce Toll-like receptor 5-mediated interleukin-8 production through mitogen-activated protein kinase and NF-kappaB activation. Infect Immun (2008) 1.07
Vibrio cholerae non-O1 serogroup associated with cholera gravis genetically and physiologically resembles O1 E1 Tor cholera strains. Infect Immun (1994) 1.06
Establishment of an adult mouse model for direct evaluation of the efficacy of vaccines against Vibrio cholerae. Infect Immun (2009) 1.03
Neutrophils are essential for containment of Vibrio cholerae to the intestine during the proinflammatory phase of infection. Infect Immun (2012) 1.02
The Vibrio cholerae mannose-sensitive hemagglutinin is the receptor for a filamentous bacteriophage from V. cholerae O139. Infect Immun (1998) 1.02
Gene encoding zonula occludens toxin (zot) does not occur independently from cholera enterotoxin genes (ctx) in Vibrio cholerae. J Clin Microbiol (1993) 1.02
Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103. Infect Immun (1990) 1.00
Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev Vaccines (2011) 1.00
The prevalence and polymorphisms of zonula occluden toxin gene in multiple Campylobacter concisus strains isolated from saliva of patients with inflammatory bowel disease and controls. PLoS One (2013) 1.00
Vibrio cholerae non-O1: production of cell-associated hemagglutinins and in vitro adherence to mucus coat and epithelial surfaces of the villi and lymphoid follicles of human small intestines treated with formalin. J Clin Microbiol (1988) 0.99
Vibrio cholerae HlyA hemolysin is processed by proteolysis. Infect Immun (1990) 0.99
A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ (1998) 0.99
Construction of a Vibrio cholerae vaccine candidate using transposon delivery and FLP recombinase-mediated excision. Infect Immun (2000) 0.98
Mechanism of membrane damage by El Tor hemolysin of Vibrio cholerae O1. Infect Immun (1996) 0.96
High-frequency spontaneous mutation of classical Vibrio cholerae to a nonmotile phenotype. Infect Immun (1990) 0.96
Role of toll-like receptor 4 in the proinflammatory response to Vibrio cholerae O1 El tor strains deficient in production of cholera toxin and accessory toxins. Infect Immun (2005) 0.94
Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs. Infect Immun (1994) 0.94
Campylobacter concisus and inflammatory bowel disease. World J Gastroenterol (2014) 0.93
Molecular cloning and nucleotide sequence analysis of cholera toxin genes of the CtxA- Vibrio cholerae strain Texas Star-SR. Infect Immun (1990) 0.93
Immunogenicity of two formulations of oral cholera vaccine comprised of killed whole vibrios and the B subunit of cholera toxin. Infect Immun (1989) 0.93
The two faces of ToxR: activator of ompU, co-regulator of toxT in Vibrio cholerae. Mol Microbiol (2011) 0.93
Differential interleukin-8 response of intestinal epithelial cell line to reactogenic and nonreactogenic candidate vaccine strains of Vibrio cholerae. Infect Immun (2001) 0.92
Induction of interleukin-8 in T84 cells by Vibrio cholerae. Infect Immun (2004) 0.89
Vibrio cholerae hemolysin is required for lethality, developmental delay, and intestinal vacuolation in Caenorhabditis elegans. PLoS One (2010) 0.88
Human immune response to Vibrio cholerae O1 whole cells and isolated outer membrane antigens. Infect Immun (1989) 0.87
Construction and analysis of a Vibrio cholerae delta-aminolevulinic acid auxotroph which confers protective immunity in a rabbit model. Infect Immun (1992) 0.86
Purification and characterization of novel toxin produced by Vibrio cholerae O1. Infect Immun (1999) 0.86
Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Clin Vaccine Immunol (2013) 0.85
Construction and characterization of a potential live oral carrier-based vaccine against Vibrio cholerae O139. Infect Immun (1996) 0.84
Characterization and immunogenicity of EX880, a Salmonella typhi Ty21a-based clone which produces Vibrio cholerae O antigen. Infect Immun (1991) 0.83
The utility of human challenge studies in vaccine development: lessons learned from cholera. Vaccine (Auckl) (2011) 0.82
Construction and characterization of a nonproliferative El Tor cholera vaccine candidate derived from strain 638. Infect Immun (2000) 0.81
Quantitative detection of Vibrio cholera toxin by real-time and dynamic cytotoxicity monitoring. J Clin Microbiol (2013) 0.80
Use of monoclonal antibodies to identify phospholipase C as the enterotoxic factor of the bifunctional hemolysin-phospholipase C molecule of Vibrio cholerae O139. Infect Immun (1998) 0.78
Isolation of viable but nonculturable Vibrio cholerae O1 from environmental water samples in Kolkata, India, in a culturable state. Microbiologyopen (2014) 0.78
Relatedness of a periplasmic, broad-specificity RNase from Aeromonas hydrophila to RNase I of Escherichia coli and to a family of eukaryotic RNases. J Bacteriol (1993) 0.78
Transcriptional responses of intestinal epithelial cells to infection with Vibrio cholerae. Infect Immun (2004) 0.77
The repertoire of glycosphingolipids recognized by Vibrio cholerae. PLoS One (2013) 0.75
Vibrio cholerae hemagglutinin(HA)/protease: An extracellular metalloprotease with multiple pathogenic activities. Toxicon (2016) 0.75
Construction of a Vibrio cholerae prototype vaccine strain O395-N1-E1 which accumulates cell-associated cholera toxin B subunit. Vaccine (2008) 0.75
Purification and characterization of a cytotonic protein expressed In vitro by the live cholera vaccine candidate CVD 103-HgR. Infect Immun (2000) 0.75
Alkaline protease from a non-toxigenic mangrove isolate of Vibrio sp. V26 with potential application in animal cell culture. Cytotechnology (2012) 0.75
Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc Natl Acad Sci U S A (1987) 15.50
Observations on the pathogenic properties of the K88, Hly and Ent plasmids of Escherichia coli with particular reference to porcine diarrhoea. J Med Microbiol (1971) 11.97
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol (1982) 4.93
Actions of cholera toxin and the prevention and treatment of cholera. Nature (1981) 4.78
A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull World Health Organ (1968) 4.53
Duration of infection-derived immunity to cholera. J Infect Dis (1981) 3.60
M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's patches: a mechanism for antigen sampling and for microbial transepithelial migration. J Infect Dis (1986) 3.32
Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis (1982) 3.28
Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature (1984) 3.08
Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga)-like cytotoxin. Lancet (1984) 3.05
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol (1986) 2.77
Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis (1974) 2.73
Non-O1 Vibrio cholerae hemolysin: purification, partial characterization, and immunological relatedness to El Tor hemolysin. Infect Immun (1984) 2.72
Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol (1985) 2.66
Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg (1979) 2.51
Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol (1985) 2.49
Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun (1984) 2.48
Enterotoxicity of El Tor-like hemolysin of non-O1 Vibrio cholerae. Infect Immun (1987) 2.46
Evaluation of the human immune response to outer membrane proteins of Vibrio cholerae. Infect Immun (1984) 2.42
Identity of hemolysins produced by Vibrio cholerae non-O1 and V. cholerae O1, biotype El Tor. Infect Immun (1986) 2.15
The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in Brazil. J Infect Dis (1982) 2.13
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun (1987) 1.89
Vibrio factors cause rapid fluid accumulation in suckling mice. Infect Immun (1983) 1.78
Selective vs. nonselective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories. J Infect Dis (1980) 1.61
Antibacterial and antitoxin responses in the serum and milk of cholera patients. Infect Immun (1981) 1.56
Hemolysin production and cloning of two hemolysin determinants from classical Vibrio cholerae. Infect Immun (1986) 1.44
Genetic susceptibility to cholera. Ann Hum Biol (1980) 1.44
Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit intestine. Infect Immun (1987) 1.20
Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae. J Infect Dis (1983) 1.15
Development of an enzyme-linked immunosorbent assay for studying Vibrio cholerae cell surface antigens. J Clin Microbiol (1982) 1.12
The problem of emesis during oral glucose-electrolytes therapy given from the onset of severe cholera. Trans R Soc Trop Med Hyg (1979) 1.06
Cytotoxin production by members of genus Vibrio. Lancet (1984) 0.97
A new enterotoxin produced by Vibrio cholerae O1. J Diarrhoeal Dis Res (1984) 0.88
Diarrheagenic Escherichia coli. Clin Microbiol Rev (1998) 30.09
Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect Immun (1991) 15.39
A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. Proc Natl Acad Sci U S A (1990) 14.22
A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc Natl Acad Sci U S A (1995) 12.79
Cholera. Clin Microbiol Rev (1995) 12.33
The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) (1977) 9.53
Pathogenicity islands and the evolution of microbes. Annu Rev Microbiol (2000) 9.51
Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med (1988) 9.19
The diarrheal response of humans to some classic serotypes of enteropathogenic Escherichia coli is dependent on a plasmid encoding an enteroadhesiveness factor. J Infect Dis (1985) 9.18
A DNA probe to identify enterohemorrhagic Escherichia coli of O157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. J Infect Dis (1987) 8.19
Detection of an adherence factor of enteropathogenic Escherichia coli with a DNA probe. J Infect Dis (1985) 7.78
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Patterns of adherence of diarrheagenic Escherichia coli to HEp-2 cells. Pediatr Infect Dis J (1987) 7.15
Experimental Campylobacter jejuni infection in humans. J Infect Dis (1988) 7.05
Plasmid-mediated adhesion in enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr (1983) 6.59
Enteropathogenic Escherichia coli contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. Proc Natl Acad Sci U S A (1995) 6.59
The complete sequence of the locus of enterocyte effacement (LEE) from enteropathogenic Escherichia coli E2348/69. Mol Microbiol (1998) 6.38
Molecular epidemiology of Vibrio cholerae in the U.S. Gulf Coast. J Clin Microbiol (1982) 6.34
Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Mol Microbiol (1998) 6.12
Cloning and characterization of the eae gene of enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol (1992) 6.09
The eae gene of enteropathogenic Escherichia coli encodes a 94-kilodalton membrane protein, the expression of which is influenced by the EAF plasmid. Infect Immun (1991) 5.75
Enteropathogenic Escherichia coli. Infect Immun (1992) 5.74
A cloned pathogenicity island from enteropathogenic Escherichia coli confers the attaching and effacing phenotype on E. coli K-12. Mol Microbiol (1997) 5.55
Plasmid-mediated factors conferring diffuse and localized adherence of enteropathogenic Escherichia coli. Infect Immun (1985) 5.42
Epidemic Yersinia enterocolitica infection due to contaminated chocolate milk. N Engl J Med (1978) 5.39
Characterization of enteroadherent-aggregative Escherichia coli, a putative agent of diarrheal disease. J Infect Dis (1988) 5.30
Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med (1994) 5.19
Cholera and other vibrioses in the United States. N Engl J Med (1985) 5.17
Bacteriophage therapy. Antimicrob Agents Chemother (2001) 5.16
A second chromosomal gene necessary for intimate attachment of enteropathogenic Escherichia coli to epithelial cells. J Bacteriol (1993) 5.02
Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol (1982) 4.93
Oxygen and the growth and metabolism of Clostridium acetobutylicum. J Gen Microbiol (1971) 4.91
A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med (1998) 4.81
The DNA sequence and analysis of human chromosome 6. Nature (2003) 4.75
A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc Natl Acad Sci U S A (1998) 4.75
Construction and analysis of TnphoA mutants of enteropathogenic Escherichia coli unable to invade HEp-2 cells. Infect Immun (1990) 4.72
Ethics and international research. BMJ (1997) 4.70
Radioimmunoassay of human serum thyrotrophin. Br Med J (1971) 4.59
Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. J Pediatr (1999) 4.57
Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest (1993) 4.53
Enteroaggregative Escherichia coli associated with persistent diarrhea in a cohort of rural children in India. J Infect Dis (1989) 4.52
Role of plasmid-encoded adherence factors in adhesion of enteropathogenic Escherichia coli to HEp-2 cells. Infect Immun (1987) 4.48
Molecular characterization of environmental and nontoxigenic strains of Vibrio cholerae. Infect Immun (1981) 4.45
A sensitive and specific DNA probe to identify enteroaggregative Escherichia coli, a recently discovered diarrheal pathogen. J Infect Dis (1990) 4.43
Quorum sensing controls expression of the type III secretion gene transcription and protein secretion in enterohemorrhagic and enteropathogenic Escherichia coli. Proc Natl Acad Sci U S A (1999) 4.42
Thyrotrophin-releasing hormone as a thyroid-function test. Lancet (1971) 4.34
Molecular evolution of a pathogenicity island from enterohemorrhagic Escherichia coli O157:H7. Infect Immun (1998) 4.33
Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med (2000) 4.29
Vibrio parahaemolyticus and related halophilic Vibrios. Crit Rev Microbiol (1982) 4.24
Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet (1988) 4.12
The Per regulon of enteropathogenic Escherichia coli : identification of a regulatory cascade and a novel transcriptional activator, the locus of enterocyte effacement (LEE)-encoded regulator (Ler). Mol Microbiol (1999) 4.12
The role of the eae gene of enterohemorrhagic Escherichia coli in intimate attachment in vitro and in a porcine model. J Clin Invest (1993) 4.11
Emerging foodborne pathogens: Escherichia coli O157:H7 as a model of entry of a new pathogen into the food supply of the developed world. Epidemiol Rev (1996) 4.09
Exclusive breastfeeding reduces acute respiratory infection and diarrhea deaths among infants in Dhaka slums. Pediatrics (2001) 4.05
A two-year study of bacterial, viral, and parasitic agents associated with diarrhea in rural Bangladesh. J Infect Dis (1980) 3.96
A plasmid-encoded type IV fimbrial gene of enteropathogenic Escherichia coli associated with localized adherence. Mol Microbiol (1992) 3.93
A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature (1999) 3.89
Cytoskeletal composition of attaching and effacing lesions associated with enteropathogenic Escherichia coli adherence to HeLa cells. Infect Immun (1992) 3.82
A plasmid-encoded regulatory region activates chromosomal eaeA expression in enteropathogenic Escherichia coli. Infect Immun (1995) 3.77
Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials. Am J Clin Nutr (2000) 3.77
Handwashing to prevent diarrhea in day-care centers. Am J Epidemiol (1981) 3.75
Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun (1984) 3.63
Duration of infection-derived immunity to cholera. J Infect Dis (1981) 3.60
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature (1987) 3.51
Harlequin syndrome: the sudden onset of unilateral flushing and sweating. J Neurol Neurosurg Psychiatry (1988) 3.47
Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus. Infect Immun (1990) 3.47
Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev (1996) 3.46
Quorum sensing is a global regulatory mechanism in enterohemorrhagic Escherichia coli O157:H7. J Bacteriol (2001) 3.43
Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci U S A (1991) 3.43
Validation of postmortem interviews to ascertain selected causes of death in children. Int J Epidemiol (1990) 3.42
Meta-analysis of intervention trials on case-management of pneumonia in community settings. Lancet (1992) 3.38
Cloning and sequencing of the genes encoding Escherichia coli cytolethal distending toxin. Infect Immun (1994) 3.36
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol (1986) 3.33
Grades of hypothyroidism. Br Med J (1973) 3.30
Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis (1982) 3.28
Non-O group 1 Vibrio cholerae gastroenteritis in the United States: clinical, epidemiologic, and laboratory characteristics of sporadic cases. Ann Intern Med (1981) 3.25
The locus of enterocyte effacement (LEE)-encoded regulator controls expression of both LEE- and non-LEE-encoded virulence factors in enteropathogenic and enterohemorrhagic Escherichia coli. Infect Immun (2000) 3.20
Use of DNA probes and HEp-2 cell adherence assay to detect diarrheagenic Escherichia coli. J Infect Dis (1988) 3.19
Vitiligo, thyroid disease and autoimmunity. Br J Dermatol (1968) 3.18
Plasmid and chromosomal elements involved in the pathogenesis of attaching and effacing Escherichia coli. Infect Immun (1991) 3.13
Effect of El Niño and ambient temperature on hospital admissions for diarrhoeal diseases in Peruvian children. Lancet (2000) 3.11
The thyrotrophin-releasing hormone test in diseases of the pituitary and hypothalamus. Lancet (1972) 3.10